Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report
| Autor: | S. Agbo-Godeau, S. Laurence, Patrick Goudot, MJ Javelot, F. Levy-Weil, Cédric Mauprivez, J. Sergheraert, Roman Hossein Khonsari |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Osteoporosis 030206 dentistry medicine.disease Surgery 03 medical and health sciences 0302 clinical medicine Otorhinolaryngology Rheumatoid arthritis Teriparatide medicine Rituximab Oral Surgery Stage (cooking) 030223 otorhinolaryngology Herpetic gingivostomatitis business Osteonecrosis of the jaw Low level laser therapy medicine.drug |
| Zdroj: | Journal of Stomatology, Oral and Maxillofacial Surgery. 121:300-304 |
| ISSN: | 2468-7855 |
| DOI: | 10.1016/j.jormas.2019.06.009 |
| Popis: | Rituximab, an anti-CD20 monoclonal antibody, is an effective treatment for rheumatoid arthritis. Here we report the case of a patient with rheumatoid arthritis, having taken risedronate for 14 months to prevent corticosteroid-induced osteoporosis, more than 2 years ago, who presented osteonecrosis of jaw following herpetic gingivostomatitis two weeks after the beginning of a rituximab treatment associated with her usual anti-rheumatic drugs. Eight weeks later, no bone and/or gum healing was observed and a stage 2 medication-related osteonecrosis of the jaw (MRONJ) was diagnosed. A conservative approach was decided with antiseptic mouth washes, low-level laser treatment (LLLT) and systemic therapy with teriparatide. Complete mucosal coverage was obtained after more two years of follow-up. We suggest that rituximab as immunosuppressant might be a cause or a decompensating factor of MRONJ. Non-surgical periodontal treatment with LLLT and teriparatide are candidates for the treatment of MRONJ. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect